本頁面由Tiger Trade Technology Pte. Ltd.提供服務

PROTEOMICS INTERNATIONAL LAB

0.140
0.000
成交量:9.57萬
成交額:1.34萬
市值:2,311.63萬
市盈率:-2.69
高:0.145
開:0.145
低:0.140
收:0.140
52周最高:0.860
52周最低:0.098
股本:1.65億
流通股本:1.22億
量比:0.95
換手率:0.08%
股息:- -
股息率:- -
每股收益(TTM):-0.052
每股收益(LYR):-0.064
淨資產收益率:-92.99%
總資產收益率:-46.46%
市淨率:3.98
市盈率(LYR):-2.20

資料載入中...

公司資料

公司名字:
PROTEOMICS INTERNATIONAL LAB
交易所:
ASX
成立時間:
2001
員工人數:
- -
公司地址:
Harry Perkins Institute of Medical Research,6 Verdun Street,Nedlands,Western Australia,Australia
郵編:
6009
傳真:
- -
簡介:
Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics. It provides PromarkerD, a predictive test for diabetic kidney disease; and develops diagnostic tests for endometriosis and giardia. The company also offers analytical services, including specialist contract research, analytical, and consultancy. Proteomics International Laboratories Ltd has a research agreement with the Busselton Population Medical Research Institute to enhance diagnosis and treatment of lung conditions, such as asthma and chronic obstructive pulmonary disease; and the Janssen Research & Development, LLC for the research of diabetic kidney and heart disease treatment. The company was founded in 2001 and is based in Perth, Australia.